efficacious
cancer treatments
significant
cardiac morbidity
biomarkers
functional
indices
early
monitoring
intervention
study
rat
model
progressive
doxorubicin
cardiomyopathy
multiple
cardiac magnetic resonance imaging
MRI
comprehensive
characterization
timecourse
serological
pathological
functional
toxicity
Hannover Wistar rats
dosed
DOX
weekly
weeks
week
off-dosing
recovery
period
Electron microscopy
myocardium
subcellular degeneration
mitochondrial
changes
single dose
Histopathological analysis
progressive
cardiomyocyte degeneration
extensive
vacuolation
doses
replacement fibrosis
quantified
Sirius red staining
off-dosing
Functional
assessed
cardiac MRI
left ventricular ejection fraction
LVEF
cardiac output
E/A ratio
statistical significance
doses
clinical
LV dysfunction
weeks
increases
myocardial
serological
cardiac troponin I
cTnI
doses
LVEF
decline
Troponin I
correlated
delayed
peak gadolinium contrast
histopathological grading
diastolic dysfunction
subcellular
cardiomyocyte degeneration
marker
progressive
functional
decline
histopathological
manifestations
Myocardial contrast enhancement
elevations
cTnI
indices
clinical
LV dysfunction
evaluation
predictive
biomarkers
